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Abstract. Background: Oropharyngeal mucositis occurs in
virtually all patients with head and neck cancer receiving
radiochemotherapy. The manipulation of the oral cavity
microbiota represents an intriguing and challenging target.
Patients and Methods: A total of 75 patients were enrolled to
receive Lactobacillus brevis CD2 lozenges or oral care
regimen with sodium bicarbonate mouthwashes. The primary
endpoint was the incidence of grade 3 or 4 oropharyngeal
mucositis during radiotherapy treatment. Results: There was
no statistical difference in the incidence of grade 3-4
oropharyngeal mucositis between the intervention and control
groups (40.6% vs. 41.6% respectively, p=0.974). The incidence
of pain, dysphagia, body weight loss and quality of life were
not different between the experimental and standard arm.
Conclusion: Our study was not able to demonstrate the efficacy
of L. brevis CD2 lozenges in preventing radiation-induced
mucositis in patients with head and neck cancer. Although
modulating homeostasis of the salivary microbiota in the oral
cavity seems attractive, it clearly needs further study. 
Acute radiation-related toxicities represent a clinically-
relevant problem during curative radiotherapy (RT) for
patients with head and neck cancer (HNC). Among different
side-effects, oropharyngeal mucositis (OM) remains one of
the most important issues for patients with HNC, with a
negative impact on their quality of life (QoL), and also on
locoregional control due to the need for treatment breaks that
extend the planned treatment time (1-6). 
The development of OM is complex and begins from
clonogenic death of basal stem cells due to DNA strand
breaks caused by reactive oxygen species (7). Through the
complex activation of several transcription factors, it seems
to end with the production of pro-inflammatory cytokines
that promote and amplify cellular damage to the oral mucosa
(8). Despite recent improvements in our understanding of
these processes, preventive and therapeutic management of
OM is still a debated and open question. A large number of
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agents, both natural and pharmacological, have been tested
with inconsistent results. To date, only oral care protocols
were recommended by the Mucositis Study Group of the
Multinational Association of Supportive Care in Cancer and
International Society of Oral Oncology and others as a
validated approach in the prevention of OM in patients with
HNC treated with curative RT (9-11).
The oral cavity is one of the most biologically complex
environments of the human body and the role of the resident
microflora in OM development during RT is still debated. To
date, interventional strategies for mucositis that focused on
manipulation of the oral cavity microbiota have been
substantially unsuccessful (12-16). Many bacteria are
implicated in the pathogenesis and maintenance of
inflammatory diseases of the oral cavity (periodontal disease,
Behcet's disease, recurrent aphthous stomatitis) and most of
them require arginine for their survival and their potential
pathogenicity (17-19).
Recently, Sharma et al. reported a statistically significant
reduction of grade 3-4 OM related to the use of
Lactobacillus brevis CD2 lozenges (LB CD2) during
radiochemotherapy (RCHT) in patients with HNC (20). 
L. brevis CD2, which produces high levels of arginine
deaminase, is able to reduce arginine availability in the oral
cavity and, therefore, reduces arginine-dependent growth of
microorganisms implicated in inflammatory processes there.
Moreover, LB CD2 reduces arginine availability for arginases,
resulting in a reduction of nitrous oxide production and a
subsequent attenuation of inflammatory processes.
Here we present the results of an Italian multi-centric,
prospective randomized trial designed to compare LB CD2
versus sodium bicarbonate mouthwash in patients with HNC
treated with RCHT or biological agent-radiotherapy (bio-
RT). The aim of the study was to verify the beneficial
effects of LB CD2 in the prevention of OM onset during the
RT course. 
Patients and Methods
This was a multicentric, phase III, open-label, randomized
controlled trial, conducted by eight Italian Oncological
Radiotherapy Departments between April 2012 and July 2015. This
study received approvals from the local clinical research Ethics
Committee and was conducted in full accordance with Helsinki
declaration (Clinical Trials number NCT01707641). All the patients
gave their informed consent.
Inclusion criteria were: Histological diagnosis of head and neck
carcinoma (except larynx, parotid and other salivary glands tumors);
age of 18 years or above; concomitant treatment with RCHT or bio-
RT in a radical setting; baseline Karnofsky performance status >70;
normal bone marrow, renal, and liver functions. Exclusion criteria
were: Inability to use mouthwash; any previous RT to the head and
neck region; major surgery approach exceeding biopsy within 4
weeks prior to the enrollment; contrast enhancement computed
tomography or positron-emission tomography for distant metastasis
detection; mucosal ulceration at baseline due to viral or mycotic
chronic disease; anti-mycotic/antiviral drugs within 1 week of
treatment start; comorbidities (insulin-dependent diabetes mellitus;
hepatitis B or C); signs and symptoms of active systemic or dental
infection. 
All patients were treated with intensity-modulated radiation
therapy (IMRT). Dose fractionation was delivered with a prescribed
total dose of 68-70 Gy and 50-54 Gy to the macroscopic disease
and low-risk regions, respectively. Concomitant cisplatinum-based
chemotherapy was administered using a weekly (40 mg/m2) or a 3-
weekly (100 mg/m2) schedule. Cetuximab was administered
concurrently with RT according to Bonner’s schedule (21). The
choice of systemic concomitant therapy was at discretion of the
attending physicians. Neo-adjuvant chemotherapy (docetaxel,
cisplatin and 5-fluorouracil every 21 days for three cycles) was
allowed for patients with nasopharyngeal cancer. 
Prior to starting RCHT or bioRT, enrolled patients were
randomised (1:1) to standard oral care regimen with sodium
bicarbonate mouthwash (control arm) or LB CD2 lozenges
(intervention arm) through a computer-generated randomization list
consisting of randomly permuted blocks of four patient numbers. 
The LB CD2 lozenges contained not less than 2×109 viable cells
of L. brevis CD2 as the active ingredient. The LB CD2 lozenges were
supplied by CD Investments Ltd, Rome, Italy. The daily dose was six
lozenges per day, one every 2-3 h to be dissolved in the mouth and
then swallowed. Hot beverages (e.g. tea, coffee, or milk) were
avoided for at least half an hour before and after administration, as
high temperature reduces the efficacy of LB CD2. The patients in the
intervention arm were to receive LB CD2 lozenges from the first day
of RT up to 1 week after the end of treatment. Patients in the control
arm received sodium bicarbonate mouthwash at least three times a
day from the first day of RT until the end of treatment. 
If patients reported grade 3-4 OM, LB CD2 tablets or standard
prophylaxis was stopped and patients started symptomatic local with
or without systemic therapies at the discretion of the single center. 
OM grade was registered weekly during the RT course by trained
physicians according to the NCI Common Toxicity Criteria scoring
system (CTCAE) version 4.0 (22).
QoL was assessed using the FACT H&N (version 4.0) quality of
life questionnaire, at the following time points: Pre-RT, at the end
of RT, and at 1, 3, 6, 9 and 12 months from the end of RCHT or
bioRT (23). Pain and dysphagia were weekly recorded during
radiotherapy by Numeric Rating Scale and according to Radiation
Therapy Oncology Group Common Toxicity Criteria, and at 1, 3, 6,
9 and 12 months from the end of RCHT or bioRT, respectively (24). 
All clinical data were collected prospectively with weekly clinic
visits during RT and at 1, 3, 6, 9 and 12 months after the end of
treatment. 
Statistical analysis. The primary endpoint of our study was to
compare the incidence of severe OM between the study group (LB
CD2 arm) and the control group (sodium bicarbonate mouthwash
arm) of patients with HNC treated with curative intent.
Secondary endpoints included: a) Number of patients who were
able to complete the planned treatment; b) requirement for enteral
nutrition; c) incidence and severity of treatment-related dysphagia;
d) patient quality of life; e) body weight loss during the treatment
course; f) the incidence and time-course of treatment-related pain.
The statistical analysis for the primary and secondary endpoints was
based on the intention-to-treat population.
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We assumed observation of severe (grade 3 and 4) OM incidence
in 75% of patients treated with sodium bicarbonate. In the group of
patients treated with LB CD2, we expected a 50% incidence of
mucositis, which was lower by 25% compared to that of the
reference group, with an odds ratio (OR) of 0.333. In order to detect
a statistically significant effect with an OR of 0.333 with α=0.05
(one-tailed) and β=0.20 (power equal to 80%), it was necessary to
enroll a total of 92 patients. Considering a patient drop out rate of
10-15%, we were required to enroll at least 106 patients (53 patients
randomized to each of the two treatment groups). 
Tumor stage and types of concomitant treatment (cisplatin,
cetuximab or neoadjuvant chemotherapy) were analyzed according
to a stepwise logistic regression analysis. 
Parametric variables were analyzed using Student’s t-test for
independent data, while the non-parametric or non-normally
distributed variables were analyzed by Mann–Whitney U-test. 
Discrete variables, nominal or categoricaI were evaluated by the
chi-square test.
The data were analyzed by using the SAS statistical software
version 9.4 (Cary, NC, USA). p-Values of 0.05 or less were
considered statistically significant. 
Results
From April 2012 to July 2015, a total of 75 patients were
enrolled. The enrollment was prematurely stopped without
achieving the planned accrual of 106 patients because the
probiotic lozenges were no longer available for the study due
to technical and administrative problems in product supply
by the company. Seven out of 75 patients were excluded
from the statistical analysis (four were considered ineligible
and were not randomized; three randomized patients
presented too high a number of missing data for all the
records available) and consequently the analysis was
performed on a sample size of 68 patients (32 in the
intervention arm and 36 in the control arm).
Patients characteristics are shown in Table I. Baseline patient
characteristics were similar for the two population arms for
age, gender, body mass index and clinical tumor stage. On the
contrary, we recorded more cases of nasopharyngeal and
hypopharyngealgeal cancer in the intervention group and more
oropharyngeal cancer in the control group. 
Nearly 80% of patients underwent cisplatinum-based
RCHT, most of them with 100 mg/cisplatin every 3 weeks:
the weekly schedule (40 mg/m2 cisplatin) was used in 6/27
(22%) patients in the intervention group and 3/23 (13%)
patients in the control group.
All patients took the LB CD2 lozenges or sodium
bicarbonate mouthwash at the planned dose, until the
occurrence of grade 3-4 OM or until the occurrence of
nausea or major clinical complications that needed systemic
supportive care. Fifteen patients discontinued the lozenges
during treatment: 11 due to lozenge-induced nausea within 2
weeks of starting treatment and four due to the occurrence
of complications that required systemic antibiotic therapy
(bleeding, pneumonia, sepsis). 
There was no serious adverse event related to LB CD2
lozenge administration.
Two early treatment-related deaths were recorded: one due
to acute renal failure (experimental arm) and one due to
acute respiratory distress syndrome (control arm).
Results showed no difference in the incidence of severe
OM between the intervention and control groups (40.6%
versus 41.6% respectively, p=0.974) during the RT course
(Table II).
From the analysis of the clinical and tumor-related
variables, a significant association was recorded only for T-
stage, regardless of the randomization arm. Patients with
stage T1-T3 had a statistically significant reduction of risk
of developing OM than patients with T4 stage (OR=0.164,
95% confidence interval=0.040-0.673; p<0.05). 
The systemic treatments categorized as neoadjuvant
chemotherapy or concurrent chemotherapy or concurrent
biotherapy did not have an impact on the development of
severe OM with respect to the randomization arm.
The QoL score was studied considering the feedback
collected from self-reported survey at baseline, at the end of
treatment and during follow-up. All but six patients
completed the QoL questionnaires during treatment, 62
patients at 1 month, 53 at 3 months, 52 at 6 months, 50 at 9
months and 42 at 12 months. These data were analyzed using
variance analysis for repeated measures. The time trend of
quality of life score was statistically different (p<0.05) among
the study phases (baseline, treatment course, follow-up).
Indeed, the QoL score tended to worsen during the treatment
course compared to the baseline condition, while during the
follow-up period, the QoL tended to recover to the baseline
level (Figure 1). No effect due to the experimental treatment
or concurrent chemotherapy was observed. Since the number
of patients who received concurrent cetuximab was very
limited, it is not possible to draw any conclusions on the
different impact on OM occurrence of these two different
concomitant systemic approaches
A statistically significant (p<0.01) tendency for weight
loss during concurrent therapy compared to the baseline was
recorded, independently of the experimental or standard arm. 
The time course of pain was statistically significant
(p<0.01). Results showed that pain increased during the
treatment phase, while in the follow-up phase it tended to
recover to baseline values, with no difference in the
experimental treatment or standard arms (Figure 2).
Regarding dysphagia, we did not observe statistically
significant differences between the two arms. On the contrary,
we recorded a statistically significant risk reduction for enteral
nutrition needs for the standard arm compared to the
experimental arm (OR=0.341, 95% confidence intervaI=0.127-
0.917; p<0.05) (Table III). Finally, the percentage of patients
who completed concomitant treatment did not differ
significantly between the two groups of patients.
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Discussion
We conducted a prospective randomized study to compare the
incidence of OM between patients treated with LB CD2
lozenges and patients treated with sodium bicarbonate
mouthwash during radical concurrent RCHT or bio-RT for
HNC. Bearing in mind the statistical limitation of the present
study (the planned accrual was not reached due to the lack of
LB CD2 supply), our results did not demonstrate any benefit
of LB CD2 in reducing the incidence of severe OM
(intervention versus control arm: 40.6% versus 41.6%,
respectively). Moreover, patients enrolled in the experimental
arm did not have any significant improvement of QoL or acute
toxicities such as weight loss, pain and dysphagia. Our study
has not confirmed the promising results obtained by Sharma
et al. (20). Sharma et al. showed that patients in the LB CD2
arm developed a significant lower rate of grade 3 and 4 OM
than those in the placebo arm (52% versus 77%, p<0.001). 
Obviously, the main bias of our study is represented by a
sample size lower than that planned. On the other hand, there
are several differences between the present study and that of
Sharma et al. which could partly explain our different
results. Firstly, IMRT was used for all our patients, while a
2D technique was employed in Sharma et al.’s study.
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Table I. Characteristics of patients at baseline.
                                                                                  LB CD2 (n=32)                                 Na Bicarbonate (n=36)                           All patients (n=68)
Gender, n (%)
  Male                                                                             26 (81.2)                                                    27 (75)                                                53 (77.9)
  Female                                                                           6 (18.8)                                                      9 (25)                                                 15 (22.1)
Mean age (range), years                                              58.4 (34-74)                                              60 (39-77)                                         60 (57.3-62.5)
Mean BMI (range), kg/m2                                       25.6 (14.8-35.2)                                       25.1 (16.2-40.1)                                   25.2 (14.8-40.1)
Primary site, n (%)
  Unknown                                                                        3 (9.4)                                                      1 (2.8)                                                  4 (5.9)
  T1                                                                                   1 (3.1)                                                      2 (5.6)                                                  3 (4.4)
  T2                                                                                 13 (40.6)                                                     8 (22)                                                 21 (30.9)
  T3                                                                                  7 (21.9)                                                   12 (33.3)                                              19 (27.9)
  T4                                                                                    8 (25)                                                     13 (36.1)                                              21 (30.9)
Nodal involvement, n (%)
  N0                                                                                   3 (9.4)                                                      2 (5.6)                                                  5 (7.4)
  N1                                                                                   3 (9.4)                                                     8 (22.2)                                               11 (16.2)
  N2                                                                                 25 (78.1)                                                  25 (69.4)                                              50 (73.5)
  N3                                                                                   1 (3.1)                                                      1 (2.8)                                                  2 (2.9)
TNM stage, n (%) 
  IIA                                                                                  2 (6.3)                                                        0 (0)                                                    2 (2.9)
  III                                                                                   5 (15.6)                                                    5 (13.9)                                               10 (14.7)
  IVA                                                                               21 (65.6)                                                  24 (66.7)                                              45 (66.2)
  IVB                                                                                 1 (3.1)                                                     4 (11.1)                                                 5 (7.4)
  Not evaluable                                                                 3 (9.4)                                                      3 (8.3)                                                  6 (8.8)
Cisplatin, n (%)                                                              27 (84.4)                                                  26 (72.2)                                              53 (77.9)
Cetuximab, n (%)                                                             3 (9.4)                                                     4 (11.1)                                                7 (10.3)
Neoadjuvant CHT, n (%)                                                 2 (6.2)                                                     6 (16.7)                                                8 (11.8)
CHT: Chemotherapy; BMI: body mass index; LB CD2: Lactobacillus brevis CD2 lozenges.
Table II. Incidence of severe oral mucositis (OM) between the
intervention and control groups.
                                     Grate 3-4 OM, n (%)
Group                        Yes                            No                       Total, n (%)
LB CD2              13 (40.6%)               19 (59.3%)                 32 (47.1%)
Control                15 (41.6 %)              21 (58.3%)                 36 (52.9%)
Total                    28 (41.2%)               40 (58.8%)                 68 (100%)
LB CD2: Lactobacillus brevis CD2 lozenges.
Table III. Incidence of requirement for enteral nutrition between the
intervention and control groups.
                                   Enteral nutrition, n (%)
Group                        Yes                            No                       Total, n (%)
LB CD2              12 (37,5%)               20 (62.5%)                 32 (47%)
Control                  6 (16.6%)               30 (83.3%)                 36 (53%)
Total                    18 (26.5%)               50 (73.5%)                 68 (100%)
LB CD2: Lactobacillus brevis CD2 lozenges.
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Figure 2. The variation of the NRS assessment for each treatment arm and chemotherapy schedule during treatment and follow-up. LB CD2:
Lactobacillus brevis CD2 lozenges; NRS: numeric rating scale (pain).
Figure 1. The variation of the quality of life score for each treatment arm and chemotherapy schedule during treatment and follow-up. LB CD2:
Lactobacillus brevis CD2 lozenges.
Nowadays, IMRT represents the best technique to improve
long-term salivary flow rates with a positive impact on QoL
(2, 11, 25). Therefore, IMRT may have improved the oral
mucosal tolerance to RCHT or bioRT in our patients,
reducing the possible beneficial impact of LB CD2 in our
experimental arm. Recently, interesting speculations have
been made about the role of IMRT in reducing the rate of
grade 3-4 OM, sparing the oral mucosa outside the planned
target volume and therefore reducing overall short- and long-
term morbidity (26, 27). Although the sparing of the oral
mucosa with IMRT seems a promising and attractive
approach in order to reduce the severity of acute mucositis
and improving QoL, the definition and contouring of the
volume of the oral mucosa in a reproducible and consistent
way still appears problematic (28). 
Radiation doses received by the mucosa of the oral cavity
and oropharynx were not recorded in our multicentric study,
hence this may be another limitation of our results. 
The analysis of the clinical and tumor-related variables
showed a significant association only for the T-stage,
regardless of the randomization arm. In particular, patients
with stage T4 had a statistically significantly greater risk of
developing OM than patients with T1-T3 stage. This may be
explained by the clinical target/planned target volumes in
patients with T4 tumor being supposedly larger than in those
with T1-T3, although we had not recorded these data. 
Furthermore, our control-arm group received sodium
bicarbonate mouthwash as recommended in several
guidelines, while the control group of Sharma et al. was
enrolled to receive placebo lozenges (9-11, 20). 
Therefore, different RT techniques and different
preventive management may explain the lower rate of severe
OM incidence in our control group (41.6%) compared to
Sharma et al.’s study (77%). 
In our experience, LB CD2 was not related to a beneficial
effect on body weight, pain and quality of life. In fact, all
these endpoints showed similar deterioration in the
intervention and control arms during treatment. As expected,
all the patients experienced symptom regression during the
first year of follow-up, with improvement also of QoL
parameters, without significant differences between the two
groups. On the contrary, patients enrolled in the standard-
treatment arm had a statistically significant lower risk of
enteral nutrition (p<0.05) compared to the experimental-
treatment arm. However, this difference should be cautiously
considered because it may reflect different enteral nutrition
supply approaches and the inhomogeneous assessment
strategies adopted by the Italian RT Departments rather than
a true statistical difference. 
We recorded interruptions of LB CD2 lozenge intake in
11/32 patients due to unpleasant taste of the lozenges. All our
patients underwent concomitant chemotherapy or biotherapy
and, therefore, were treated with antiemetic drugs. Although
antiemetic therapy was modulated to correct increasing
nausea, 34.3% of patients discontinued taking LB CD2. 
Despite our results, the modulation of oral cavity
environment remains a promising field because the salivary
microbiota plays an important role in homeostasis of the oral
cavity (13-14). At present, studies that demonstrated efficacy
in modulating the salivary microbiota were mainly focused on
non-neoplastic diseases of the oral cavity. In this setting, a
favorable microbiota balance and a recovery of a healthy oral
environment are more easily achieved, allowing resolution of
the disease (17-19, 29). On the contrary, controversial results
have been shown between the presence/manipulation of
specific bacterial species and mucositis occurrence in patients
treated with radiotherapy for HNC. Many differences between
in bacterial strains studied, study population, collection time,
sampling methods, and scoring methods for mucositis make it
impossible to draw any conclusions from these studies (15, 16,
30-32). Nevertheless, the concept that disease conditions such
as OM may be associated with a shift in the microbial
composition of the biofilm that colonizes the oral cavity
continues to attract more and more attention. In fact, the
alteration of the salivary bacterial flora due to tumor itself or
RCHT may contribute to mucosal damage, modulating the
levels of opportunistic bacteria that can turn pathogenic in
patients with cancer who develop OM (8, 14). There is also
much emphasis on the role of conditions of other oral sites
such as supra- and subgingival periodontitis, although few
studies have looked into these conditions (33, 34).
OM induced by RT is, therefore, a complex process that
must be tackled from various therapeutic perspectives.
Salivary microbiota may represent an intriguing therapeutic
perspective and be worthy of further research.
In conclusion, while considering that the statistical power
of the study suffered due to the premature closure of patient
accrual, we were not able to confirm the beneficial effects of
L. brevis CD2 in reducing the rate of grade 3-4 RT-induced
OM in patients with HNC.
Further larger prospective studies are required to explore
the impact of modulation of the oral cavity environment in
reducing the incidence and severity of OM in this setting of
patients. 
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